Voyager Therapeutics (STU:VT6) LT-Debt-to-Total-Asset : 0.09 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Voyager Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.09.

Voyager Therapeutics's long-term debt to total assets ratio increased from Mar. 2023 (0.06) to Mar. 2024 (0.09). It may suggest that Voyager Therapeutics is progressively becoming more dependent on debt to grow their business.

Voyager Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Voyager Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics LT-Debt-to-Total-Asset Chart

Voyager Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.17

0.20

0.13

0.05

Voyager Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.06	0.06	0.05	0.09

Voyager Therapeutics LT-Debt-to-Total-Asset Calculation

Voyager Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	15.674	/	322.125
	=	0.05

Voyager Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	38.635	/	432.025
	=	0.09

Voyager Therapeutics (STU:VT6) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Voyager Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics (STU:VT6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

VYGR:USA VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (STU:VT6) Headlines

No Headlines